BACKGROUND: The dysbindin (DTNBP1 [dystrobrevin-binding protein 1]) gene has repeatedly been shown to be associated with schizophrenia across diverse populations. One study also showed that risk haplotypes were shared with a bipolar disorder subgroup with psychotic episodes, but not with all cases. DTNBP1 may confer susceptibility to psychotic symptoms in various psychiatric disorders besides schizophrenia. METHODS: Methamphetamine psychosis, the psychotic symptoms of which are close to those observed in schizophrenia, was investigated through a case (n = 197)-control (n = 243) association analyses of DTNBP1. RESULTS: DTNBP1 showed significant associations with methamphetamine psychosis at polymorphisms of P1635 (rs3213207, p = .00003) and SNPA (rs2619538, p = .049) and the three-locus haplotype of P1655 (rs2619539)-P1635-SNPA (permutation p = .0005). The C-A-A haplotype, which was identical to the protective haplotype previously reported for schizophrenia and psychotic bipolar disorders, was a protective factor (p = .0013, odds ratio [OR] = .62, 95% confidence interval [CI] .51-.77) for methamphetamine psychosis. The C-G-T haplotype was a risk for methamphetamine psychosis (p = .0012, OR = 14.9, 95% CI 3.5-64.2). CONCLUSIONS: Our genetic evidence suggests that DTNBP1 is involved in psychotic liability not only for schizophrenia but also for other psychotic disorders, including substance-induced psychosis.
BACKGROUND: The dysbindin (DTNBP1 [dystrobrevin-binding protein 1]) gene has repeatedly been shown to be associated with schizophrenia across diverse populations. One study also showed that risk haplotypes were shared with a bipolar disorder subgroup with psychotic episodes, but not with all cases. DTNBP1 may confer susceptibility to psychotic symptoms in various psychiatric disorders besides schizophrenia. METHODS:Methamphetaminepsychosis, the psychotic symptoms of which are close to those observed in schizophrenia, was investigated through a case (n = 197)-control (n = 243) association analyses of DTNBP1. RESULTS:DTNBP1 showed significant associations with methamphetaminepsychosis at polymorphisms of P1635 (rs3213207, p = .00003) and SNPA (rs2619538, p = .049) and the three-locus haplotype of P1655 (rs2619539)-P1635-SNPA (permutation p = .0005). The C-A-A haplotype, which was identical to the protective haplotype previously reported for schizophrenia and psychotic bipolar disorders, was a protective factor (p = .0013, odds ratio [OR] = .62, 95% confidence interval [CI] .51-.77) for methamphetaminepsychosis. The C-G-T haplotype was a risk for methamphetaminepsychosis (p = .0012, OR = 14.9, 95% CI 3.5-64.2). CONCLUSIONS: Our genetic evidence suggests that DTNBP1 is involved in psychotic liability not only for schizophrenia but also for other psychotic disorders, including substance-induced psychosis.
Authors: Rasmon Kalayasiri; Viroj Verachai; Joel Gelernter; Apiwat Mutirangura; Robert T Malison Journal: Addiction Date: 2014-03-17 Impact factor: 6.526
Authors: Joanne Voisey; Christopher D Swagell; Ian P Hughes; Jason P Connor; Bruce R Lawford; Ross M Young; C Phillip Morris Journal: Behav Brain Funct Date: 2010-07-09 Impact factor: 3.759
Authors: Dong-Hwan Yun; Chi-Un Pae; Antonio Drago; Laura Mandelli; Diana De Ronchi; Ashwin A Patkar; In Ho Paik; Alessandro Serretti; Jung-Jin Kim Journal: Psychiatry Investig Date: 2008-06-30 Impact factor: 2.505
Authors: E Yokobayashi; H Ujike; T Kotaka; Y Okahisa; M Takaki; M Kodama; T Inada; N Uchimura; M Yamada; N Iwata; M Iyo; I Sora; N Ozaki; S Kuroda Journal: Curr Neuropharmacol Date: 2011-03 Impact factor: 7.363
Authors: Kathleen M Grant; Tricia D LeVan; Sandra M Wells; Ming Li; Scott F Stoltenberg; Howard E Gendelman; Gustavo Carlo; Rick A Bevins Journal: J Neuroimmune Pharmacol Date: 2011-07-05 Impact factor: 4.147
Authors: Alexandre A Guerin; Eric J Nestler; Michael Berk; Andrew J Lawrence; Susan L Rossell; Jee Hyun Kim Journal: Neurosci Biobehav Rev Date: 2020-11-17 Impact factor: 8.989